Policy

Covid-19: India to export hydroxychloroquine to ‘badly affected’ countries

Amiti Sen New Delhi | Updated on April 07, 2020 Published on April 07, 2020

Hydroxychloroquine   -  Reuters

Decision amid Trump’s threat of retaliation if India doesn’t allow hydroxychloroquine exports

India has indicated that export orders for Hydroxychloroquine (HCQ), an anti-malarial drug being experimentally used in many countries for treating COVID-19, could be allowed to be released if companies had enough stock.

The statement made by the Ministry of External Affairs on Tuesday is important in the light of a recent threat made by US President Donald Trump of retaliatory action against India if its demand for HCQ supplies is not met by this developing country .

Commerce Ministry officials say that while export of the drug has been completely banned by the Directorate General of Foreign Trade (DGFT) through a notification issued on April 4, exports can be made only if the export policy is relaxed at the Minister’s level to allow shipments.

“Policy relaxation can be given by the DGFT through the policy relaxation committee, but policy relaxation has to be given by the Commerce Minister,” the official told BusinessLine.

 

Going by the MEA’s recent statement, it seems India may be ready to give policy relaxation for HCQ. ”About paracetamol and HCQ, they will be kept in a licensed category, and their demand position would be continuously monitored. However, the stock position could allow our companies to meet the export commitments that they had contracted,” said Anurag Srivastava, Spokesperson, MEA, in response to queries.

He further said that given the humanitarian aspects of the pandemic, it has been decided that India would licence paracetamol and HCQ in appropriate quantities to all our neighbouring countries who are dependent on our capabilities, and to some nations who have been particularly badly affected by the pandemic.

“Since the US is one of the nations most affected by COVID-19 virus, it would certainly fall in the category of nations badly affected by the pandemic that India seeks to help out by supplying HCQ. But we will have to wait for our orders,” the official said.

In a telephone conversation with Prime Minister Narendra Modi recently, Trump had sought the release of the orders for HCQ made by Washington. India had imposed import prohibition on the medicine on March 23 to ensure enough availability for the domestic population with exports allowed under limited conditions, including humanitarian grounds. However, on April 4, a revised notification was issued by the DGFT, placing a complete prohibition on HCQ exports without any exception.

Trump said at a White House press conference on Monday that the US could take retaliatory action against India if it doesn’t sell the drug to his country.

There are more than 3,65,000 confirmed COVID-19 cases in the US with close to 11,000 deaths. In India, the number of infected is close to 5,000 with around 136 deaths.

Published on April 07, 2020

A letter from the Editor


Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Support Quality Journalism
This article is closed for comments.
Please Email the Editor
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.